{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T01:55:01Z","timestamp":1772502901393,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jneuroim.2024.578330","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T02:44:36Z","timestamp":1710384276000},"page":"578330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series"],"prefix":"10.1016","volume":"389","author":[{"given":"Edward H.","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd A.","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jneuroim.2024.578330_bb0005","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s40265-019-01140-x","article-title":"Siponimod: First Global Approval","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jneuroim.2024.578330_bb0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/cells8010024","article-title":"Mechanism of Siponimod: anti-inflammatory and neuroprotective mode of action","volume":"8","author":"Behrangi","year":"2019","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.jneuroim.2024.578330_bb0015","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1352458509357065","article-title":"Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results: clinical and laboratory research","volume":"16","author":"Comi","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2024.578330_bb0020","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.52017","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: a practical review","author":"Coyle","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"9","key":"10.1016\/j.jneuroim.2024.578330_bb0025","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1007\/s00415-022-11166-z","article-title":"Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study","volume":"269","author":"Gold","year":"2022","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2024.578330_bb0030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"10127","key":"10.1016\/j.jneuroim.2024.578330_bb0035","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2024.578330_bb0040","series-title":"Conference Proceedings 2016 Asia Pacific Lymphology Conference","article-title":"The prevalence of chronic lower limb oedema (CLLO) in multiple sclerosis (MS)","author":"Keeley","year":"2016"},{"issue":"7","key":"10.1016\/j.jneuroim.2024.578330_bb0045","article-title":"Fingolimod-associated macular edema in the treatment of multiple sclerosis","volume":"15","author":"Khan","year":"2023","journal-title":"Cereus"},{"issue":"8","key":"10.1016\/j.jneuroim.2024.578330_bb0050","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1111\/bcp.14752","article-title":"Drug-induced peripheral oedema: an aetiology-based review","volume":"87","author":"Largeau","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.jneuroim.2024.578330_bb0055","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2217\/nmt-2019-0024","article-title":"Diagnosis and management of secondary-progressive multiple sclerosis: time for change","volume":"9","author":"Oh","year":"2019","journal-title":"Neurodegenerat. Dis. Manag."},{"issue":"11","key":"10.1016\/j.jneuroim.2024.578330_bb0060","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1136\/jnnp-2013-307282","article-title":"Oral ponesimod in relapsing\u2013remitting multiple sclerosis: a randomised phase II trial","volume":"85","author":"Olsson","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2024.578330_bb0065","first-page":"61","article-title":"Ponesimod in the treatment of relapsing forms of multiple sclerosis: an update on the emerging clinical data","volume":"12","author":"Ruggieri","year":"2022","journal-title":"Degenerat. Neurol. Neuromusc. Dis."},{"issue":"11","key":"10.1016\/j.jneuroim.2024.578330_bb0070","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40263-020-00771-z","article-title":"Siponimod: a review in secondary progressive multiple sclerosis","volume":"34","author":"Scott","year":"2020","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.jneuroim.2024.578330_bb0075","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/1352458506070681","article-title":"Prevalence of oedema of the lower limbs in multiple sclerosis patients: a vascular and lymphoscintigraphic study","volume":"12","author":"Solaro","year":"2006","journal-title":"Mult. Scler. J."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572824000481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572824000481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T23:46:50Z","timestamp":1712188010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572824000481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":15,"alternative-id":["S0165572824000481"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578330","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578330","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"578330"}}